2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Prof Aron Goldhirsch MD

Prof Richard D Gelber PhD

Prof Martine J Piccart-Gebhart MD

Evandro de Azambuja MD

Marion Procter MSci

Prof Thomas M Suter MD

Prof Christian Jackisch MD

Prof David Cameron MD

Harald A Weber MD

Dominik Heinzmann PhD

Lissandra Dal Lago MD

Eleanor McFadden MA

Prof Mitch Dowsett PhD

Prof Michael Untch MD

Luca Gianni MD

Prof Richard Bell MD

Prof Claus-Henning Köhne MD

Anita Vindevoghel MD

Michael Andersson MD

Professor Adrian Brunt m.brunt@keele.ac.uk

Douglas Otero-Reyes MD

Santai Song MD

Prof Ian Smith MD

Brian Leyland-Jones PhD †

Prof Jose Baselga MD †